Combination therapies for hypertension enjoy robust sales

Major drug makers, who have been marketing combined formulations of ARB+CCB for the treatment of hypertension, enjoyed robust sales growth last year, industry data showed.

According to the data released by the Ubist, a drug information service agency, Novatis’s Exforge with a combined formulation of amlodipine, a dihydropyridine calcium-channel blocker (CCB), and valsartan, an angiotensin re...